SPDR S&P Pharmaceuticals ETF Price & Performance (XPH)

SPDR S&P Bank ETF (KBE) experienced a surge in put option trading on Friday, with 5,030 contracts purchased, nearly double its usual volume. This heightened activity suggests increased investor caution, possibly linked to the ETF’s recent performance within its 52-week range of $42.77 to $63.74.1

Citadel, led by Ken Griffin, has made a significant £305 million short position against GSK, representing 0.51% of its shares. This move comes amid concerns over the pharmaceutical giant’s long-term pipeline, particularly as key patents near expiration. GSK’s shares have underperformed, declining 17.53% over five years.2

SPDR S&P MidCap 400 ETF Trust (MDY) saw increased activity from institutional investors, with Assetmark Inc. boosting its holdings by 112% in Q4. The ETF, trading at $535.74, has a market cap of $22.17 billion and a 52-week range of $511.97 to $624.13, reflecting its mid-cap focus.3